Speaker Name:  Dr. Christoph Wanner, Professor of Medicine, Chief-Division of Nephrology & Hypertension, University Hospital of Wurzburg, Germany.

Watch this session to:

• Recognize the clinical importance of early DKD detection using eGFR and UACR to enable timely risk reduction strategies.
• Review landmark evidence supporting SGLT2i for slowing CKD progression and improving cardiorenal outcomes.
• Understand the evolving multi-pillar treatment approach incorporating RAS blockade, SGLT2i, and Finerenone.
• Interpret contemporary KDIGO, ADA, and ESC guidance for organ-protective management in DKD.
• Evaluate the place of DPP-4 inhibitors, including Linagliptin, in glycemic control for patients with advanced CKD.